Symbols / MNKD $2.56 +2.40% MannKind Corporation
MNKD Chart
About
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 788.74M |
| Enterprise Value | 1.07B | Income | 5.86M | Sales | 348.97M |
| Book/sh | -0.17 | Cash/sh | 0.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 591 | IPO | — |
| P/E | 128.00 | Forward P/E | 11.25 | PEG | — |
| P/S | 2.26 | P/B | -15.42 | P/C | — |
| EV/EBITDA | 18.18 | EV/Sales | 3.07 | Quick Ratio | 1.41 |
| Current Ratio | 1.71 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.02 | EPS next Y | 0.23 | EPS Growth | — |
| Revenue Growth | 45.80% | Earnings | 2026-05-07 | ROA | 4.91% |
| ROE | — | ROIC | — | Gross Margin | 74.79% |
| Oper. Margin | -6.87% | Profit Margin | 1.68% | Shs Outstand | 308.10M |
| Shs Float | 302.43M | Short Float | 7.48% | Short Ratio | 2.99 |
| Short Interest | — | 52W High | 6.51 | 52W Low | 2.23 |
| Beta | 1.04 | Avg Volume | 5.99M | Volume | 3.18M |
| Target Price | $7.50 | Recom | Strong_buy | Prev Close | $2.50 |
| Price | $2.56 | Change | 2.40% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Wedbush | Outperform → Outperform | $8 |
| 2026-02-27 | down | RBC Capital | Outperform → Sector Perform | $4 |
| 2026-02-27 | main | Wells Fargo | Overweight → Overweight | $7 |
| 2026-02-27 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2026-02-25 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2026-01-26 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-11-24 | init | Truist Securities | — → Buy | $9 |
| 2025-11-11 | main | RBC Capital | Outperform → Outperform | $8 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $8 |
| 2025-10-13 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-09-05 | main | Oppenheimer | Outperform → Outperform | $15 |
| 2025-09-03 | main | Wells Fargo | Overweight → Overweight | $10 |
| 2025-09-02 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-08-26 | main | RBC Capital | Outperform → Outperform | $8 |
| 2025-08-07 | main | RBC Capital | Outperform → Outperform | $7 |
| 2025-07-25 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-07-23 | main | RBC Capital | Outperform → Outperform | $8 |
| 2025-04-10 | init | Mizuho | — → Outperform | $12 |
| 2024-12-20 | init | Wells Fargo | — → Overweight | $9 |
- How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential - Yahoo Finance Mon, 23 Mar 2026 07
- MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill hu, 02 Apr 2026 07
- Why MannKind Stock Tumbled on Thursday - The Motley Fool hu, 26 Feb 2026 08
- MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha Wed, 18 Mar 2026 07
- Why MannKind (MNKD) Is Down 40.8% After Earnings Miss And New Tyvaso DPI Rival Appears - simplywall.st Sun, 01 Mar 2026 08
- MannKind (MNKD) CEO receives large PRSU and stock option grants tied to TSR - Stock Titan Wed, 25 Mar 2026 07
- Is MannKind Corporation (MNKD) one of the popular penny stocks on Robinhood to buy? - MSN ue, 31 Mar 2026 17
- $MNKD stock is down 34% today. Here's what we see in our data. - Quiver Quantitative Wed, 25 Feb 2026 08
- Reassessing MannKind (MNKD) After Sharp Recent Share Price Declines - Yahoo Finance Fri, 27 Feb 2026 08
- MannKind (MNKD) EVP receives new performance RSU and option awards - Stock Titan Wed, 25 Mar 2026 07
- MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza - MSN Sat, 28 Mar 2026 13
- How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance Sun, 08 Mar 2026 08
- MannKind closes note deal with $35.5M cash and 569,023 shares - Stock Titan hu, 05 Mar 2026 08
- MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets - Yahoo Finance Wed, 04 Mar 2026 08
- MannKind (MNKD) CFO receives performance-based RSUs and long-term stock options - Stock Titan Wed, 25 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
348.97
+22.23%
|
285.50
+43.50%
|
198.96
+99.42%
|
99.77
|
| Operating Revenue |
|
402.92
+18.75%
|
339.30
+32.85%
|
255.39
+155.98%
|
99.77
|
| Cost Of Revenue |
|
87.96
+14.83%
|
76.60
+22.03%
|
62.77
+9.17%
|
57.50
|
| Reconciled Cost Of Revenue |
|
79.65
+15.05%
|
69.23
+18.88%
|
58.24
+1.29%
|
57.50
|
| Gross Profit |
|
261.01
+24.94%
|
208.90
+53.39%
|
136.19
+222.17%
|
42.27
|
| Operating Expense |
|
214.46
+52.94%
|
140.22
+11.64%
|
125.60
+12.95%
|
111.19
|
| Research And Development |
|
66.35
+44.57%
|
45.89
+46.70%
|
31.28
+58.63%
|
19.72
|
| Selling General And Administration |
|
144.13
+52.80%
|
94.33
+0.02%
|
94.31
+3.11%
|
91.47
|
| Selling And Marketing Expense |
|
—
|
—
|
51.78
-3.68%
|
53.75
|
| General And Administrative Expense |
|
—
|
—
|
42.54
+12.77%
|
37.72
|
| Other Gand A |
|
—
|
—
|
42.54
+12.77%
|
37.72
|
| Other Operating Expenses |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
302.42
+39.48%
|
216.82
+15.11%
|
188.37
+11.66%
|
168.69
|
| Operating Income |
|
46.55
-32.22%
|
68.68
+548.29%
|
10.59
+115.37%
|
-68.92
|
| Total Operating Income As Reported |
|
38.80
-46.55%
|
72.59
+736.45%
|
8.68
+113.54%
|
-64.11
|
| EBITDA |
|
51.51
-31.92%
|
75.66
+295.90%
|
19.11
+133.93%
|
-56.32
|
| Normalized EBITDA |
|
65.67
-25.79%
|
88.49
+317.46%
|
21.20
+135.21%
|
-60.20
|
| Reconciled Depreciation |
|
12.28
+66.65%
|
7.37
+62.54%
|
4.54
-28.15%
|
6.31
|
| EBIT |
|
39.23
-42.56%
|
68.29
+368.51%
|
14.58
+123.27%
|
-62.63
|
| Total Unusual Items |
|
-14.16
-10.37%
|
-12.83
-514.96%
|
-2.09
-153.78%
|
3.88
|
| Total Unusual Items Excluding Goodwill |
|
-14.16
-10.37%
|
-12.83
-514.96%
|
-2.09
-153.78%
|
3.88
|
| Special Income Charges |
|
-6.41
+61.70%
|
-16.73
-9744.12%
|
-0.17
|
0.00
|
| Other Special Charges |
|
—
|
20.44
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.00
+100.00%
|
-5.26
|
0.00
|
0.00
|
| Write Off |
|
6.41
+313.48%
|
1.55
+811.76%
|
0.17
|
0.00
|
| Net Income |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Pretax Income |
|
1.41
-95.39%
|
30.52
+394.09%
|
-10.38
+88.13%
|
-87.40
|
| Net Non Operating Interest Income Expense |
|
-29.98
-18.17%
|
-25.37
-33.46%
|
-19.01
+14.60%
|
-22.26
|
| Interest Expense Non Operating |
|
37.82
+0.13%
|
37.77
+51.37%
|
24.95
+0.74%
|
24.77
|
| Net Interest Income |
|
-29.98
-18.17%
|
-25.37
-33.46%
|
-19.01
+14.60%
|
-22.26
|
| Interest Expense |
|
37.82
+0.13%
|
37.77
+51.37%
|
24.95
+0.74%
|
24.77
|
| Interest Income Non Operating |
|
8.05
-36.16%
|
12.62
+104.99%
|
6.15
+144.89%
|
2.51
|
| Interest Income |
|
8.05
-36.16%
|
12.62
+104.99%
|
6.15
+144.89%
|
2.51
|
| Other Income Expense |
|
-15.17
-18.53%
|
-12.80
-551.53%
|
-1.96
-152.00%
|
3.78
|
| Other Non Operating Income Expenses |
|
-1.01
-3253.13%
|
0.03
-73.77%
|
0.12
+219.61%
|
-0.10
|
| Gain On Sale Of Security |
|
-7.75
-298.34%
|
3.91
+303.91%
|
-1.92
-149.39%
|
3.88
|
| Tax Provision |
|
-4.46
-252.08%
|
2.93
+87.70%
|
1.56
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+118.75%
|
0.00
-54.29%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-2.97
-141.43%
|
-1.23
-181.12%
|
-0.44
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Net Income From Continuing Operation Net Minority Interest |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Net Income From Continuing And Discontinued Operation |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Net Income Continuous Operations |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Normalized Income |
|
17.05
-56.49%
|
39.18
+480.80%
|
-10.29
+88.73%
|
-91.28
|
| Net Income Common Stockholders |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Diluted EPS |
|
0.02
-80.00%
|
0.10
+350.00%
|
-0.04
+88.24%
|
-0.34
|
| Basic EPS |
|
0.02
-80.00%
|
0.10
+350.00%
|
-0.04
+88.24%
|
-0.34
|
| Basic Average Shares |
|
305.64
+11.38%
|
274.42
+2.77%
|
267.01
+3.86%
|
257.09
|
| Diluted Average Shares |
|
314.11
+10.66%
|
283.84
+6.30%
|
267.01
+3.86%
|
257.09
|
| Diluted NI Availto Com Stockholders |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Amortization |
|
3.97
|
0.00
|
0.00
|
—
|
| Amortization Of Intangibles Income Statement |
|
3.97
|
0.00
|
0.00
|
—
|
| Depreciation Amortization Depletion Income Statement |
|
3.97
|
0.00
|
0.00
|
—
|
| Depreciation And Amortization In Income Statement |
|
3.97
|
0.00
|
0.00
|
—
|
| Total Other Finance Cost |
|
0.21
-0.96%
|
0.21
+0.48%
|
0.21
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
475.20
|
| Current Assets |
|
373.39
|
| Cash Cash Equivalents And Short Term Investments |
|
295.10
|
| Cash And Cash Equivalents |
|
238.48
|
| Cash Financial |
|
—
|
| Other Short Term Investments |
|
56.62
|
| Receivables |
|
14.90
|
| Accounts Receivable |
|
14.90
|
| Gross Accounts Receivable |
|
23.74
|
| Allowance For Doubtful Accounts Receivable |
|
-8.84
|
| Inventory |
|
28.55
|
| Raw Materials |
|
6.26
|
| Work In Process |
|
13.65
|
| Finished Goods |
|
8.64
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
—
|
| Other Current Assets |
|
34.85
|
| Total Non Current Assets |
|
101.81
|
| Net PPE |
|
84.22
|
| Gross PPE |
|
185.76
|
| Accumulated Depreciation |
|
-101.54
|
| Properties |
|
0.00
|
| Land And Improvements |
|
0.88
|
| Buildings And Improvements |
|
63.75
|
| Machinery Furniture Equipment |
|
72.14
|
| Construction In Progress |
|
49.00
|
| Goodwill And Other Intangible Assets |
|
3.00
|
| Goodwill |
|
1.93
|
| Other Intangible Assets |
|
1.07
|
| Investments And Advances |
|
7.16
|
| Other Non Current Assets |
|
7.43
|
| Total Liabilities Net Minority Interest |
|
721.37
|
| Current Liabilities |
|
104.12
|
| Payables And Accrued Expenses |
|
44.07
|
| Payables |
|
11.14
|
| Accounts Payable |
|
9.58
|
| Current Accrued Expenses |
|
32.93
|
| Total Tax Payable |
|
1.56
|
| Income Tax Payable |
|
1.56
|
| Current Debt And Capital Lease Obligation |
|
20.00
|
| Current Debt |
|
20.00
|
| Other Current Borrowings |
|
20.00
|
| Current Capital Lease Obligation |
|
—
|
| Current Deferred Liabilities |
|
10.51
|
| Current Deferred Revenue |
|
9.09
|
| Other Current Liabilities |
|
28.94
|
| Total Non Current Liabilities Net Minority Interest |
|
617.24
|
| Long Term Debt And Capital Lease Obligation |
|
252.62
|
| Long Term Debt |
|
248.70
|
| Long Term Capital Lease Obligation |
|
3.92
|
| Tradeand Other Payables Non Current |
|
—
|
| Non Current Deferred Liabilities |
|
69.79
|
| Non Current Deferred Revenue |
|
69.79
|
| Other Non Current Liabilities |
|
294.77
|
| Stockholders Equity |
|
-246.17
|
| Common Stock Equity |
|
-246.17
|
| Capital Stock |
|
2.70
|
| Common Stock |
|
2.70
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
270.03
|
| Ordinary Shares Number |
|
270.03
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
2,980.54
|
| Retained Earnings |
|
-3,229.41
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
-246.17
|
| Total Capitalization |
|
2.53
|
| Working Capital |
|
269.27
|
| Invested Capital |
|
22.53
|
| Total Debt |
|
272.62
|
| Net Debt |
|
30.22
|
| Capital Lease Obligations |
|
3.92
|
| Net Tangible Assets |
|
-249.17
|
| Tangible Book Value |
|
-249.17
|
| Available For Sale Securities |
|
—
|
| Current Provisions |
|
0.60
|
| Held To Maturity Securities |
|
7.16
|
| Interest Payable |
|
2.15
|
| Investmentin Financial Assets |
|
7.16
|
| Non Current Accrued Expenses |
|
0.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
18.25
-57.06%
|
42.51
+24.69%
|
34.09
+142.26%
|
-80.68
|
| Cash Flow From Continuing Operating Activities |
|
18.25
-57.06%
|
42.51
+24.69%
|
34.09
+142.26%
|
-80.68
|
| Net Income From Continuing Operations |
|
5.86
-78.75%
|
27.59
+331.09%
|
-11.94
+86.34%
|
-87.40
|
| Depreciation Amortization Depletion |
|
12.28
+66.65%
|
7.37
+62.54%
|
4.54
-28.15%
|
6.31
|
| Depreciation |
|
12.28
+66.65%
|
7.37
+62.54%
|
4.54
-28.15%
|
6.31
|
| Depreciation And Amortization |
|
12.28
+66.65%
|
7.37
+62.54%
|
4.54
-28.15%
|
6.31
|
| Other Non Cash Items |
|
4.89
-15.97%
|
5.82
+320.30%
|
1.38
-88.45%
|
11.99
|
| Stock Based Compensation |
|
24.20
+13.28%
|
21.36
+21.02%
|
17.65
+31.25%
|
13.45
|
| Asset Impairment Charge |
|
10.40
+169.70%
|
3.85
-15.72%
|
4.57
+107.72%
|
2.20
|
| Operating Gains Losses |
|
14.16
-21.72%
|
18.09
+767.07%
|
2.09
+153.78%
|
-3.88
|
| Gain Loss On Investment Securities |
|
6.41
+313.48%
|
1.55
+811.76%
|
0.17
-81.76%
|
0.93
|
| Net Foreign Currency Exchange Gain Loss |
|
7.75
+298.34%
|
-3.91
-303.91%
|
1.92
+139.83%
|
-4.81
|
| Gain Loss On Sale Of PPE |
|
—
|
0.56
|
0.00
|
0.00
|
| Change In Working Capital |
|
-50.88
-39.51%
|
-36.47
-318.02%
|
16.73
+169.55%
|
-24.05
|
| Change In Receivables |
|
-4.76
-279.56%
|
2.65
+13.09%
|
2.35
+119.86%
|
-11.81
|
| Changes In Account Receivables |
|
-4.76
-279.56%
|
2.65
+13.09%
|
2.35
+119.86%
|
-11.81
|
| Change In Inventory |
|
-6.62
-107.26%
|
-3.20
+71.83%
|
-11.35
-100.12%
|
-5.67
|
| Change In Prepaid Assets |
|
-10.03
-52.60%
|
-6.57
+10.17%
|
-7.32
+52.94%
|
-15.55
|
| Change In Payables And Accrued Expense |
|
-18.42
-235.53%
|
-5.49
-206.97%
|
5.13
+52.18%
|
3.37
|
| Change In Accrued Expense |
|
3.26
+220.46%
|
-2.70
-140.92%
|
6.61
+1013.69%
|
-0.72
|
| Change In Payable |
|
-21.68
-677.62%
|
-2.79
-89.27%
|
-1.47
-135.96%
|
4.10
|
| Change In Account Payable |
|
-16.71
-499.39%
|
-2.79
-89.27%
|
-1.47
-135.96%
|
4.10
|
| Change In Other Working Capital |
|
-8.26
+46.06%
|
-15.31
-138.80%
|
39.46
+179.93%
|
14.10
|
| Change In Other Current Assets |
|
-1.91
+46.53%
|
-3.57
-1457.41%
|
0.26
-49.71%
|
0.52
|
| Change In Other Current Liabilities |
|
-0.87
+82.48%
|
-4.98
+57.81%
|
-11.81
-30.95%
|
-9.02
|
| Investing Cash Flow |
|
-304.80
-215.37%
|
-96.65
-4761.62%
|
-1.99
-140.79%
|
4.87
|
| Cash Flow From Continuing Investing Activities |
|
-304.80
-215.37%
|
-96.65
-4761.62%
|
-1.99
-140.79%
|
4.87
|
| Net PPE Purchase And Sale |
|
-4.57
+52.89%
|
-9.69
+77.16%
|
-42.44
-459.24%
|
-7.59
|
| Purchase Of PPE |
|
-4.57
+52.89%
|
-9.69
+77.16%
|
-42.44
-459.24%
|
-7.59
|
| Capital Expenditure |
|
-4.57
+52.89%
|
-9.69
+77.16%
|
-42.44
-459.24%
|
-7.59
|
| Net Investment Purchase And Sale |
|
57.51
+166.13%
|
-86.96
-314.96%
|
40.45
+45.49%
|
27.80
|
| Purchase Of Investment |
|
-157.80
+43.80%
|
-280.80
-255.01%
|
-79.09
+0.55%
|
-79.54
|
| Sale Of Investment |
|
215.31
+11.08%
|
193.84
+62.14%
|
119.55
+11.37%
|
107.34
|
| Net Business Purchase And Sale |
|
-347.74
|
0.00
|
0.00
+100.00%
|
-15.34
|
| Purchase Of Business |
|
-347.74
|
0.00
|
0.00
+100.00%
|
-15.34
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Net Other Investing Changes |
|
-10.00
-2625.25%
|
0.40
+3.66%
|
0.38
|
—
|
| Financing Cash Flow |
|
315.10
+329.55%
|
-137.27
-200.48%
|
136.61
+538.71%
|
21.39
|
| Cash Flow From Continuing Financing Activities |
|
315.10
+329.55%
|
-137.27
-200.48%
|
136.61
+538.71%
|
21.39
|
| Net Issuance Payments Of Debt |
|
325.00
+344.05%
|
-133.17
-1897.42%
|
-6.67
|
0.00
|
| Issuance Of Debt |
|
325.00
|
0.00
|
0.00
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-133.17
-1897.42%
|
-6.67
|
0.00
|
| Long Term Debt Issuance |
|
325.00
|
0.00
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-133.17
-1897.42%
|
-6.67
|
0.00
|
| Net Long Term Debt Issuance |
|
325.00
+344.05%
|
-133.17
-1897.42%
|
-6.67
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
6.89
-65.20%
|
19.79
|
| Proceeds From Stock Option Exercised |
|
1.99
-36.54%
|
3.14
+72.47%
|
1.82
-34.20%
|
2.77
|
| Net Other Financing Charges |
|
-11.89
-64.34%
|
-7.24
-105.38%
|
134.57
+11621.15%
|
-1.17
|
| Changes In Cash |
|
28.55
+114.92%
|
-191.40
-213.45%
|
168.71
+410.04%
|
-54.42
|
| Beginning Cash Position |
|
47.08
-80.26%
|
238.48
+241.82%
|
69.77
-43.82%
|
124.18
|
| End Cash Position |
|
75.63
+60.65%
|
47.08
-80.26%
|
238.48
+241.82%
|
69.77
|
| Free Cash Flow |
|
13.69
-58.29%
|
32.82
+493.17%
|
-8.35
+90.54%
|
-88.27
|
| Interest Paid Supplemental Data |
|
14.72
-15.94%
|
17.51
-4.23%
|
18.28
+106.50%
|
8.85
|
| Income Tax Paid Supplemental Data |
|
1.71
-60.00%
|
4.26
|
0.00
|
—
|
| Amortization Of Securities |
|
-2.65
+48.02%
|
-5.09
-450.49%
|
-0.93
-230.83%
|
0.71
|
| Change In Income Tax Payable |
|
-4.97
|
0.00
|
0.00
|
—
|
| Change In Interest Payable |
|
—
|
—
|
0.00
|
0.00
|
| Change In Tax Payable |
|
-4.97
|
0.00
|
0.00
|
—
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
6.89
-65.20%
|
19.79
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
6.89
-65.20%
|
19.79
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-25 View
- 42026-03-25 View
- 42026-03-25 View
- 42026-03-25 View
- 42026-03-25 View
- 42026-03-25 View
- 42026-03-10 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-01-09 View
- 42025-12-29 View
- 42025-12-19 View
- 42025-12-16 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|